Castle Biosciences Inc. has announced new data from clinical studies demonstrating the value of its DecisionDx®-Melanoma test in guiding sentinel lymph node biopsy (SLNB) decisions and predicting recurrence risk in patients with cutaneous melanoma. The findings will be presented in two oral sessions at the 2nd European Congress on Dermato-Oncology, scheduled for November 17-18, 2025, in Paris, France. A multicenter study involving 810 patients with early-stage, SLN-negative cutaneous melanoma found that the DecisionDx-Melanoma test serves as an independent predictor of recurrence and improves risk assessment beyond American Joint Committee on Cancer (AJCC) staging alone. Patients with high-risk (Class 2B) results showed significantly lower five-year recurrence-free survival compared to those with lower-risk classifications. The addition of DecisionDx-Melanoma results to AJCC staging increased prognostic accuracy, supporting its potential to enhance surgical planning and patient management.